SequelSEC

TransMedics Group, Inc. TMDX

Electromedical & Electrotherapeutic Apparatus · CIK 0001756262 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$668.47M
Fiscal year ended 2026-06-30
Operating income
$81.61M
Fiscal year ended 2026-06-30
Free cash flow
$79.04M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.43BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$129.06Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income23.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue7.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity9.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Effective tax rate-77.0%0th
FCF margin22.1%100th
Net margin31.4%100th
Operating margin17.9%96th
Current ratio7.14x93th
CapEx / revenue9.8%90th
Revenue YoY growth37.1%82th
R&D / revenue11.4%32th
SBC / revenue6.1%48th
Gross margin59.9%52th

TransMedics Group, Inc. (TMDX) reported revenue of $668.47M and net income of $151.70M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TransMedics Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

TransMedics Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$668.47M
Cost of revenue$276.12M
Gross profit$392.35M
Operating income$81.61M
Net income$151.70M
Research & development$92.47M
Weighted-average diluted sharesUnavailable
Pretax income$72.55M
Income tax expense-$79.14M
Diluted EPSUnavailable
Selling, general & administrative$218.27M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

TransMedics Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$1.46B
Current assets$651.12M
Total liabilities$946.34M
Current liabilities$98.28M
Total equity incl. NCI$518.05M
Temporary (mezzanine) equityUnavailable
Inventory$54.14M
Accounts receivable$104.14M
Goodwill$11.55M
Long-term debtUnavailable
Accounts payable$12.91M

Cash flow

TransMedics Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$145.93M
Capital expenditures$66.89M
Investing cash flow-$66.89M
Financing cash flow$11.47M
Net change in cash$90.04M
Stock-based compensation$37.09M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$36.42M

Derived

TransMedics Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$79.04M
Gross margin58.7%
Operating margin12.2%
FCF margin11.8%
SBC / revenue5.5%
Current ratio6.62x
Revenue YoY growth25.8%
Net margin22.7%
R&D / revenue13.8%
CapEx / revenue10.0%
Long-term debt / equityUnavailable
Effective tax rate-109.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TMDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADMT AXGN BLFS CBLL CNMD CV ECOR ELMD ESMC FOCL GTHP HCIL

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.